Chagas disease: still a neglected emergency?
- 1 April 2020
- journal article
- letter
- Published by Elsevier BV in The Lancet
- Vol. 395 (10230), 1113-1114
- https://doi.org/10.1016/s0140-6736(20)30171-9
Abstract
No abstract availableFunding Information
- Medtronic
- Pfizer
- GlaxoSmithKline
- Amgen
- Bristol-Myers Squibb
- Sanofi
This publication has 5 references indexed in Scilit:
- A new framework for managing extremely preterm birthsThe Lancet, 2019
- Post hoc analyses of SHIFT and PARADIGM‐HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: “Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial” by Bocchi et al.ESC Heart Failure, 2018
- Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic CardiomyopathyCirculation: Heart Failure, 2017
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureThe New England Journal of Medicine, 2014
- The Reality of Heart Failure in Latin AmericaJournal of Invasive Cardiology, 2013